Difference between revisions of "Team:Peking/Improve"

Line 348: Line 348:
 
                                  
 
                                  
 
                                 <div class="content">
 
                                 <div class="content">
                                     <p>What's more, we fused Frb-yEGFP with HOtag6 and fused FKBP-yEGFP with HOtag3. These two parts can form phase separation in the presence of rapamycin (Fig. 2). The original part <a href="http://parts.igem.org/Part:BBa_K209496">BBa_K209496</a> (Frb) and <a href="http://parts.igem.org/Part:BBa_K209496">BBa_K209023</a> (FKBP) have not this function. We uploaded 2 parts: <a href="http://parts.igem.org/Part:BBa_K2601010">BBa_K2601010</a> (Frb-yEGFP-HOTag6) and <a href="http://parts.igem.org/Part:BBa_K2601011">BBa_K2601011</a> (FKBP-yEGFP-HOTag3). </p>
+
                                     <p>What's more, we fused Frb-yEGFP with HOtag6 and fused FKBP-yEGFP with HOtag3. These two parts can form phase separation in the presence of rapamycin (Fig. 2). The original part <a href="http://parts.igem.org/Part:BBa_K209496">BBa_K209496</a> (Frb) and <a href="http://parts.igem.org/Part:BBa_K209496">BBa_K209023</a> (FKBP) have not this function. We uploaded 2 parts: <a href="http://parts.igem.org/Part:BBa_K2601010">BBa_K2601010</a> (Frb-yEGFP-HOTag6) and <a href="http://parts.igem.org/Part:BBa_K2601011">BBa_K2601011</a> (FKBP-yEGFP-HOTag3).<br/>
 +
 
 +
Then, we drive the expression of Frb-yEGFP-HOTag6 with 3 promoters pUra3, pTEF1 and PDH3. As our <a href="https://2018.igem.org/Team:Peking/Model">Modeling</a> work predicts, the kinetics of a system depends on the concentration of the components and the interaction strength(Fig .3).
 +
 
 +
 
 +
<br/>
 +
</p>
 +
 
  
 
                                 </div>
 
                                 </div>

Revision as of 21:16, 16 October 2018

Improvement

In this section, you could see the Improvement.

Fuse with yEGFP

We fuse part BBa_K209496 (Frb) and BBa_K209023 (FKBP) with yEGFP, which make it visible in the yeast under fluorescent microscope. Then we got partBBa_K2601008(FKBP-yEGFP) and BBa_K2601007(Frb-yEGFP).

Afterward, we drive the expression of FKBP-yEGFP and Frb-yEGFP with 4 promoters pUra3, pTet07,pTEF1 and PDH3. The expression of these promoters were measure by flow cytometry(Fig. 1). We then got prats BBa_K2601021 (Tet07-Frb-yEGFP), K2601023 (PDH3-Frb-yEGFP), BBa_K2601025 (Tet07-FKBP-yEGFP), BBa_K2601026 (TEF1-FKBP-yEGFP), K2601027 (PDH3-FKBP-yEGFP).




What's more, we fused Frb-yEGFP with HOtag6 and fused FKBP-yEGFP with HOtag3. These two parts can form phase separation in the presence of rapamycin (Fig. 2). The original part BBa_K209496 (Frb) and BBa_K209023 (FKBP) have not this function. We uploaded 2 parts: BBa_K2601010 (Frb-yEGFP-HOTag6) and BBa_K2601011 (FKBP-yEGFP-HOTag3).
Then, we drive the expression of Frb-yEGFP-HOTag6 with 3 promoters pUra3, pTEF1 and PDH3. As our Modeling work predicts, the kinetics of a system depends on the concentration of the components and the interaction strength(Fig .3).